Atlas Trials

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Clinical trial NCT05592483 · TERMINATED

Trial details

NCT number
NCT05592483
Sponsor
AstraZeneca
Status
TERMINATED
Study type
OBSERVATIONAL
Breast Cancer
Start date
2023-07-07
Primary completion
2024-05-29
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.